Regeneron Pharmaceuticals
REGN
563 hedge funds and large institutions have $34.1B invested in Regeneron Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 231 increasing their positions, 177 reducing their positions, and 49 closing their positions.
49% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 49
31% more repeat investments, than reductions
Existing positions increased: 231 | Existing positions reduced: 177
14% more funds holding in top 10
Funds holding in top 10: 22 → 25 (+3)
4% more funds holding
Funds holding: 541 → 563 (+22)
10% less capital invested
Capital invested by funds: $37.7B → $34.1B (-$3.63B)
25% less call options, than puts
Call options by funds: $678M | Put options by funds: $905M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$296M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$160M |
| 3 |
Two Sigma Advisers
New York
|
+$123M |
| 4 |
Two Sigma Investments
New York
|
+$116M |
| 5 |
MCM
Marsico Capital Management
Denver,
Colorado
|
+$103M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$530M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$258M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$178M |
| 4 |
Morgan Stanley
New York
|
-$176M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$173M |
REGN Hedge Fund Activity: Q3 2015 in Review
563 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2015, worth a combined $34.1B — down 9.6% from $37.7B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new REGN positions and 49 closed out — a net gain of 24 holders — while 231 added to existing stakes and 177 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $296M. The largest seller was Capital World Investors, cutting an estimated $530M.
- 563 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2015, up from 541 in Q2 2015.
- Funds reported $34.1B of Regeneron Pharmaceuticals stock for Q3 2015, down 9.6% quarter-over-quarter.
- 73 funds opened new Regeneron Pharmaceuticals positions in Q3 2015 and 49 closed out, a net change of +24 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2015 was T. Rowe Price Associates, an estimated $296M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2015 was Capital World Investors, an estimated $530M sold.
Based on aggregated 13F filings for Q3 2015.